In patients with non-dialysis CKD, a high urinary angiotensinogen (UAGT) level is linked with adverse renal outcomes, according to a study published in Biomolecules. Soo Wan Kim, PhD, and colleagues analyzed the link in 1,688 patients with non-dialysis CKD, with a median follow-up of approximately 6 years. Patients were divided by UAGT to urine creatinine ratio (UAGT/Cr) level. Decline in kidney function and onset of ESRD were the primary outcomes. Compared with that of the first quartile, the risk for composite renal event was notably higher in the fifth quintile (adjusted HR, 1.528; 95% CI, 1.156-2.021). In sensitivity analyses, the correlation between adverse renal outcome and high UAGT/Cr level remained consistent, including the analysis of the cause-specific hazard model. Certain clinical factors, such as albuminuria and BMI, acted as modifiers of the link between UAGT level and renal outcomes in the subgroup analyses. “Further studies are warranted to elaborate and expand the predictive role of UAGT as a biomarker for renal outcomes in CKD,” Dr. Kim and colleagues wrote.
- Business of Medicine
- Doctor’s Voice